

GLENN et al. – Appln. No. 09/257,188

DRAFT

23. (2x Amended) A method for potentiating an antigen-specific immune response in a subject comprising:

- a. pretreating an area of skin of said subject, whereby said pretreating disrupts at least the skin's stratum corneum but does not penetrate the skin's dermis;
- b. applying an adjuvant formulation to said pretreated area, wherein said adjuvant formulation comprises:

- 1) at least one adjuvant present in an amount effective to promote said immune response and

- 2) a pharmaceutically acceptable carrier, wherein said pretreating enhances skin penetration by said adjuvant formulation; and

- c. administering to said subject a separate antigen formulation comprising at least one antigen sufficient to induce an antigen-specific immune response against a pathogen; such that said at least one antigen is processed by an antigen presenting cell and then presented to a lymphocyte to induce said immune response, and said at least one adjuvant potentiates said immune response.

28. (2x Amended) A method for potentiating an antigen-specific immune response in a subject comprising:

- a. pretreating an area of the skin of said subject, whereby said pretreating disrupts at least the skin's stratum corneum but does not penetrate the skin's dermis;
- b. applying an antigen formulation to said pretreated area, wherein said antigen formulation comprises:

- 1) at least one antigen sufficient to induce an antigen-specific immune response against a pathogen and

- 2) a pharmaceutically acceptable carrier, wherein said pretreating enhances skin penetration by said antigen formulation; and

- c. administering to said subject a separate adjuvant formulation comprising at least one adjuvant in an amount effective to promote said immune response;

GLENN et al. - Appln. No. 09/257,188

DRAFT

such that said at least one antigen is processed by an antigen presenting cell and then presented to a lymphocyte to induce said immune response, and said at least one adjuvant potentiates said immune response.

Kindly add the following new claims.

92. (New) The method of claim 23, wherein said separate antigen formulation is administered at said pretreated area of skin.

93. (New) The method of claim 23, wherein said separate antigen formulation is administered at a site different from said pretreated area of skin.

94. (New) The method of claim 28, wherein said separate adjuvant formulation is administered at said pretreated area of skin.

95. (New) The method of claim 28, wherein said separate adjuvant formulation is administered at a site different from said pretreated area of skin.